Full text
Earnings transcript
Read the complete earnings call transcript.
HRMY
Harmony Biosciences Holdings, Inc.
$27.74
-0.22
(-0.79%)
[ms_data_label text=’Delayed data’]
| Exchange: | NASDAQ |
| Market Cap: | 1.604B |
| Shares Outstanding: | 49.239M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Biotechnology | |||||
| CEO: | Jeffrey Dayno | |||||
| Full Time Employees: | 268 | |||||
| Address: |
| |||||
| Website: | https://www.harmonybiosciences.com |
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 582,022 | 714,734 | 868,453 |
| Gross Profit | 460,786 | 557,919 | 670,111 |
| EBITDA | 221,512 | 233,412 | 255,048 |
| Operating Income | 192,030 | 190,826 | 208,469 |
| Net Income | 128,853 | 145,493 | 158,687 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 811,448 | 999,200 | 1,271,631 |
| Total Liabilities | 344,456 | 340,045 | 401,413 |
| Total Stockholders Equity | 466,992 | 659,155 | 870,218 |
| Total Debt | 193,566 | 179,266 | 20,000 |
| Cash and Cash Equivalents | 311,660 | 453,001 | 752,502 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 219,387 | 219,821 | 0 |
| Capital Expenditure | -312 | -1,153 | 0 |
| Free Cash Flow | 219,075 | 218,668 | 0 |
| Net Income | 128,853 | 145,493 | 0 |
| Net Change in Cash | 67,396 | 141,341 | 0 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 974,130.332 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 1,153,980.685 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 1,085,136.107 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 309,963.144 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 367,190.580 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 345,284.598 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 230,789.138 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 288,142.913 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 266,188.699 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 342,722.977 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 405,998.748 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 381,777.535 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 4.550 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 4.920 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 3.940 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 4 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 3 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Strong Revenue Performance: HRMY has demonstrated robust revenue growth as reported in recent income statements, reflecting effective product market penetration and operational efficiency. This aligns with positive trends in the biotechnology industry, as indicated by sector performance metrics.
- Healthy Profitability Metrics: Key metrics such as gross profit margin TTM and net profit margin TTM indicate strong profitability compared to industry averages, showcasing HRMY’s ability to manage costs and generate returns for shareholders.
- Solid Cash Flow Generation: Free cash flow yield TTM and operating cash flow from cash flow statements highlight HRMY’s capacity to generate cash, providing financial flexibility for reinvestment or debt management.
- Focused Innovation: Insights from earnings call transcripts emphasize HRMY’s commitment to research and development, positioning the company to maintain a competitive edge through innovative product offerings in the healthcare sector.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates HRMY intrinsic value between $55.37 – $55.60 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about HRMY valuation
Is Harmony Biosciences Holdings, Inc. (HRMY) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Harmony Biosciences Holdings, Inc. (HRMY) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is HRMY a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether HRMY trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is HRMY’s P/E ratio?
You can see HRMY’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for HRMY?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is HRMY a good long-term investment?
Whether HRMY fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
HRMY
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
[ms_data_label text="Daily snapshot"]
-0.79
Trading Metrics:
| Open: | [ms_cell_or_dash table='trading_quote' column='open'] | Previous Close: | [ms_cell_or_dash table='trading_quote' column='previousClose'] | |
| Day Low: | [ms_cell_or_dash table='trading_quote' column='dayLow'] | Day High: | [ms_cell_or_dash table='trading_quote' column='dayHigh'] | |
| Year Low: | 25.52 | Year High: | 40.87 | |
| Price Avg 50: | 31.52 | Price Avg 200: | 33.26 | |
| Volume: | 501779 | Average Volume: | 937211 |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeHRMY full analysis
Welcome to MARKETSNAP’s SWOT analysis for Harmony Biosciences! If you’re a long-term investor looking to dig into a unique player in the biotech space, you’ve come to the right place. Today, we’re breaking down Harmony Biosciences—known on the ticker as HRMY—a company that’s carving out its niche in the pharmaceutical industry, specifically focusing on innovative treatments for rare neurological disorders. Let’s unpack what makes this company tick, dive into recent developments, and analyze its potential through a detailed SWOT framework.…
